A Comparison Between the Efficacy of Venlafaxine and Duloxetine in Improving Chemotherapy-Induced Chronic Neurotoxicity in Cancer Patients

سال انتشار: 1402
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 176

فایل این مقاله در 5 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IEJM-12-2_005

تاریخ نمایه سازی: 7 خرداد 1402

چکیده مقاله:

Background: Chemotherapy-induced peripheral neuropathy is one of the most common side effects of chemotherapy. This study aimed to determine the effectiveness of venlafaxine and duloxetine in improving chronic neurotoxicity induced by chemotherapy in cancer patients.Materials and Methods: The study was performed on cancer patients undergoing outpatient chemotherapy or hospitalization in Rasoul Akram hospital. The admitted patients were blindly divided into two groups. The first group was treated with venlafaxine, and the second group was treated with duloxetine. The treatment lasted up until the patients’ full recovery up to ۱۰ weeks. Different intensities of the patients’ neuropathy were measured on all days of treatment based on NCI Common Terminology Criteria for Adverse Events (CTCAE) v ۳.۰ criteria. At the end of the treatment, the side effects of venlafaxine and duloxetine were identified.Results: A total of ۳۰ patients in two groups (n=۱۵ for each group) were treated with venlafaxine and duloxetine. There was no significant difference between the two groups in terms of age and gender. The severity of neuropathy was significantly reduced in the venlafaxine compared to the duloxetine group from ۷ to ۱۰ weeks. The results indicated that ۷۵% and ۸۵.۷% fall asleep in the venlafaxine group and the duloxetine group, respectively. Further, there was no significant difference between the two groups in terms of drug side effects.Conclusion: This study showed that venlafaxine is a suitable drug for the treatment of chronic neurotoxicity in patients with relatively fewer side effects compared to other used drugs. Although these results require further prospective studies due to the small sample size, future drug regimens may preferably contain venlafaxine.

نویسندگان

Hanzaleh Jour Ebrahimiyan

Department of Hematology and Medical Oncology, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, Iran

Nafise Ansarinejad

Department of Hematology and Medical Oncology, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, Iran

Farshid Fardad

Department of Hematology and Medical Oncology, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, Iran